指南与共识乳腺癌

PIK3CA/AKT1/PTEN基因检测与临床应用专家共识(2026版)

[Expert consensus on detection and clinical application of alterations in PIK3CA/AKT1/PTEN genes (2026 edition)].
指南 / 共识 · Zhonghua Zhong Liu Za Zhi · 2026-01-01

中国抗癌协会乳腺癌专业委员会等三机构牵头多学科专家制订本共识,基于系统文献检索与GRADE分级,阐述PIK3CA/AKT1/PTEN检测的临床意义、技术规范、治疗决策及不良反应管理,为HR+/HER-2-乳腺癌精准治疗提供标准化框架。

要点

  • PIK3CA/AKT1/PTEN改变是HR+/HER-2-乳腺癌内分泌及CDK4/6抑制剂耐药核心机制之一。
  • 中国数据显示约60%乳腺癌患者存在PI3K/AKT通路基因改变。
  • 卡匹色替、伊那利塞、阿培利司等靶向药已获批,共识规范检测与用药。

核心结论

  • 共识为PIK3CA/AKT1/PTEN基因检测与临床应用提供标准化框架,指导靶向治疗合理应用。

研究设计与样本

  • 中国抗癌协会乳腺癌专业委员会、肿瘤病理专业委员会及国家肿瘤质控中心乳腺癌专家委员会牵头多学科专家制订。
  • 基于PubMed、Embase、Cochrane Library及中国知网、万方等数据库系统文献检索,采用GRADE证据分级。

主要发现

  • PIK3CA/AKT1/PTEN改变是HR+/HER-2-乳腺癌对内分泌治疗、CDK4/6抑制剂及抗HER-2治疗耐药的核心机制之一。
  • 中国数据显示约60%的乳腺癌患者存在PI3K/AKT通路基因改变。
  • AKT抑制剂卡匹色替及PI3K抑制剂伊那利塞、阿培利司已获批,显著改善对应基因改变患者的生存。

关键数值与推荐

  • 共识系统阐述PIK3CA/AKT1/PTEN检测的临床意义、技术规范、治疗决策、不良反应管理及未来研究方向。

临床怎么用

  • 为临床医师、病理工作者及医疗机构提供实践指导,规范检测流程与靶向药物合理应用。
  • 适用于HR+/HER-2-乳腺癌患者的分子检测与治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Breast cancer is the most common malignancy among women worldwide, with a continuously increasing incidence, posing a major public health threat to women's health. In recent years, with advances in molecular biology and innovations in diagnostic and therapeutic technologies, the management of breast cancer has evolved from histopathological classification to an era of individualized precision medicine guided by molecular characteristics. PIK3CA/AKT1/PTEN alterations represent one of the key mechanisms underlying resistance to endocrine therapy, CDK4/6 inhibitors, and anti-HER-2 therapies in hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER-2-) breast cancer. Data from China indicate that approximately 60% of patients with breast cancer harbor genetic alterations in PI3K/AKT pathway. Multiple agents targeting these alterations have been approved domestically and internationally, including the AKT inhibitor capivasertib and the PI3K inhibitors inavolisib and alpelisib, which have significantly improved survival outcomes in patients with corresponding genomic alterations. To standardize testing procedures and guide the rational use of targeted therapies, the Breast Cancer Expert Committee of China Anti-Cancer Association, the Society of Tumor Pathology of China Anti-Cancer Association, and the Breast Cancer Expert Committee of the National Cancer Quality Control Center jointly led a multidisciplinary panel of experts from breast surgery, medical oncology, pathology, pharmacy, and related fields to develop this consensus based on systematic literature searches of PubMed, Embase, the Cochrane Library, as well as Chinese databases such as CNKI and Wanfang, and guided by the GRADE evidence grading system. This consensus comprehensively addresses the clinical significance of PIK3CA/AKT1/PTEN testing, technical specifications, therapeutic decision-making, adverse event management, and future research directions. It aims to provide a standardized framework for clinical practice and institutional workflow in this field, offering practical guidance for clinicians, pathologists, and healthcare institutions, and ultimately maximizing the benefits of precision medicine for patients with breast cancer. 乳腺癌作为全球女性常见恶性肿瘤,其发病率持续升高,已成为威胁女性健康的重大公共卫生问题。近年来,随着分子生物学研究的深入和诊疗技术的革新,乳腺癌的治疗模式已从传统的病理分型全面迈入以分子特征为导向的个体化精准医疗时代。PIK3CA/AKT1/PTEN基因的异常改变是激素受体阳性人表皮生长因子受体2(HER-2)阴性乳腺癌对内分泌治疗、CDK4/6抑制剂及抗HER-2治疗耐药的核心机制之一。中国数据显示,约60%的乳腺癌患者存在PI3K/AKT通路基因改变。针对这些基因改变的多种药物已在国内外获批上市,包括AKT抑制剂卡匹色替、PI3K抑制剂伊那利塞和阿培利司,显著改善了对应基因改变患者的生存。为规范检测流程并指导靶向药物地合理应用,中国抗癌协会乳腺癌专业委员会与中国抗癌协会肿瘤病理专业委员会、国家肿瘤质控中心乳腺癌专家委员会牵头,汇聚乳腺外科、肿瘤内科、病理科、药学等多学科专家,基于对PubMed、Embase、Cochrane Library及中国知网、万方数据知识服务平台等数据库的系统性文献检索及GRADE证据分级标准制订了《PIK3CA/AKT1/PTEN基因检测与临床应用专家共识(2026版)》,系统阐述了PIK3CA/AKT1/PTEN基因检测的临床意义、技术规范、治疗决策、不良反应管理及未来探索方向。共识旨在为该领域的临床实践与医疗机构流程建设提供标准化框架,为临床医师、病理工作者及相关医疗机构提供实践指导,最终使广大乳腺癌患者从精准医学的发展中最大化获益。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. [Expert consensus on detection and clinical application of alterations in PIK3CA/AKT1/PTEN genes (2026 edition)]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42927945. doi:10.3760/cma.j.cn112152-20260430-00218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。